• News
  • SAN DIEGO
  • BioTech

TSRI launches new drug discovery initiative

The Scripps Research Institute (TSRI) recently announced the formation of Scripps Advance, a new drug discovery initiative to translate early-stage biomedical research projects, both internal and external to TSRI, into clinical development candidates.

Scripps Advance’s first collaborator in this endeavor is the Johnson & Johnson Innovation Center in California, which will tap into Scripps Advance’s strong ties with academic researchers at TSRI, other academic centers and early stage companies to help identify potential collaborators.

As part of the relationship, Advance will facilitate match-making between Johnson & Johnson Innovation and emerging life science companies, companies-in-planning, researchers conducting translational research and entrepreneurs that are part of Scripps Advance’s network.

Scripps Advance has already been active in the biotech space, collaborating with Atlas Venture, an early stage investment firm, to launch a company called Padlock Therapeutics. Padlock discovers novel therapeutics targeting the protein arginine deiminases (PADs), an emerging class of enzymes with roles in autoimmunity and epigenetic control. Padlock’s technology was developed in the laboratories of TSRI investigators Paul Thompson, Ph.D., and Kerri Mowen, Ph.D., in collaboration with the Scripps Florida’s high-throughput screening facility.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Subscribe Today!